Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer

被引：0
|
作者：
Amadori, D.
Gasparini, G.
Ardizzoni, A.
Comella, G.
Saracchini, S.
Barone, C.
Bordonaro, R.
Djazouli, K.
Barbalo, A.
机构：
[1] Ist Sci Romagnolo Studio & Lacura Tumori, Meldola, Forli Cesena, Italy
[2] Azienda Complesso Osped S Filippo Neri, Rome, Italy
[3] AO Univ Parma, Parma, Italy
[4] Fondaz G Pascale, Naples, Italy
[5] AO Santa Maria Angeli, Pordenone, Italy
[6] Policlin Univ A Gemelli, Rome, Italy
[7] Azienda Garibaldi, Catania, Italy
[8] Cephalon Europe, Paris, France
[9] Cephalon Srl, Rome, Italy
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：247S / 247S
页数：1
相关论文
共 50 条
  • [1] Phase I-II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab as first-line treatment of patients with her-2/neu positive locally-advanced or metastatic breast cancer
    Amadori, D.
    Gasparini, G.
    Di Blasio, B.
    Di Costanzo, F.
    Lunardi, G.
    Vannozzi, M. O.
    Serra, P.
    Milandri, C.
    ANNALS OF ONCOLOGY, 2005, 16 : 12 - 12
  • [2] Liposomal doxorubicin in combination with trastuzumab and docetaxel as first line chemotherapy in HER-2 metastatic breast cancer patients
    Bighin, C.
    Puglisi, F.
    Cavazzini, G.
    Olmeo, N.
    Colucci, G.
    Garrone, O.
    Paccagnella, A.
    Labianca, R.
    Crino, L.
    Simoncini, E.
    Manzione, L.
    Nardi, M.
    Cortesi, E.
    Venturini, M.
    ANNALS OF ONCOLOGY, 2005, 16 : 9 - 9
  • [3] Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) in patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)
    Baselga, J.
    Climent, M. A.
    Lluch, A.
    Hornedo, J.
    Gascon, R.
    Sanchez, A. T.
    Guillem, V.
    Cortes-Funes, H.
    Regueiro, P.
    Trigo, J.
    EJC SUPPLEMENTS, 2004, 2 (03): : 132 - 132
  • [4] A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCET®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer
    Vanturini, M.
    Bighin, C.
    Puglisi, F.
    Contu, A.
    Aitini, E.
    Colucci, G.
    Merlano, M. C.
    Paccagnella, A.
    Marini, G.
    Crino, L.
    Djazouli, K.
    Barbato, A.
    CANCER RESEARCH, 2009, 69 (02) : 249S - 249S
  • [5] A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer
    Amadori, D.
    Milandri, C.
    Comella, G.
    Saracchini, S.
    Salvagni, S.
    Barone, C.
    Bordonaro, R.
    Gebbia, V.
    Barbato, A.
    Serra, P.
    Gattuso, D.
    Nanni, O.
    Baconnet, B.
    Gasparini, G.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2091 - 2098
  • [6] Liposomal doxorubicin Myocet® in combination with Herceptin® and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer:: a phase II study
    Trigo, J
    Climent, MA
    Lluch, A
    Gascon, P
    Hornedo, J
    Gil, M
    Cirera, L
    Guillem, V
    Regueiro, P
    Baselga, J
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S83 - S83
  • [7] Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
    Rocca, Andrea
    Cortesi, Pietro
    Cortesi, Laura
    Gianni, Lorenzo
    Matteucci, Federica
    Fantini, Lorenzo
    Maestri, Antonio
    Giunchi, Donata Casadei
    Cavanna, Luigi
    Ciani, Rosa
    Falcini, Fabio
    Bagni, Antonella
    Meldoli, Elena
    Dall'Agata, Monia
    Volpi, Roberta
    Andreis, Daniele
    Nanni, Oriana
    Curcio, Annalisa
    Lucchi, Leonardo
    Amadori, Dino
    Fedeli, Anna
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [8] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] THE EFFICACY AND SAFETY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN MYOCET AND DOCETAXEL AS FRONT LINE TREATMENT IN HER2-NEU NEGATIVE METASTATIC BREAST CANCER PATIENTS: RESULTS OF A PHASE II TRIAL
    Cals, L.
    Facchini, T.
    Dohollou, N.
    Nouryegat, P.
    Lortholary, A.
    Gomez, P.
    Levy, E.
    Bressac, C.
    Gligorov, J.
    Jaubert, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 67 - 67
  • [10] Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer
    Najagami, K.
    Inoue, K.
    Mizutani, M.
    Hozumi, Y.
    Fujiwara, Y.
    Masuda, N.
    Tsukamoto, F.
    Saito, M.
    Ohashi, Y.
    Sano, M.
    Noguchi, S.
    CANCER RESEARCH, 2009, 69 (02) : 241S - 242S
12345